David Zaccardelli

CIK: 0001627642

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)26 (56.5%)

Position reduction

Option Exercises (M)5 (10.9%)

Derivative conversions

Awards (A)9 (19.6%)

Compensation grants

Other (G, F, J, C, D, …)6 (13.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (3)

VOR

Vor Biopharma Inc.

Director

SABS

SAB Biotherapeutics, Inc.

Director

VRNA

Verona Pharma plc

DirectorOfficer

Discretionary Trading P&L

Holdings

Transaction History (46 total)

VOR
Vor Biopharma Inc.
Jul 7, 2026
Award(A)
Stock Option (Right to Buy)
Direct
42.7K shares-
SABS
SAB Biotherapeutics, Inc.
Jan 5, 2026
Award(A)
Stock Option (right to buy)
Direct
240K shares-
VRNA
Verona Pharma plc
Oct 7, 2025
Exercise(M)
Direct
3.3M shares-
VRNA
Verona Pharma plc
Oct 7, 2025
Award(A)
Restricted Share Unit
Direct
1.6M shares-
VRNA
Verona Pharma plc
Oct 7, 2025
Disposition(D)
Direct
3.3M shares-
VRNA
Verona Pharma plc
Oct 7, 2025
Disposition(D)
Direct
12.2M shares-
VRNA
Verona Pharma plc
Aug 29, 2025
Gift(G)
Direct
1.2M shares-
VRNA
Verona Pharma plc
Aug 1, 2025
Exercise(M)
Direct
255.7K shares-
VRNA
Verona Pharma plc
Aug 1, 2025
Sale(S)
Direct
208.9K shares at avg. $13.14$2.7M
VRNA
Verona Pharma plc
Jul 8, 2025
Tax Payment(F)
Direct
90.3K shares at avg. $11.44$1.0M
VRNA
Verona Pharma plc
Jul 7, 2025
Award(A)
Restricted Share Units
Direct
675K shares-
VRNA
Verona Pharma plc
Jul 7, 2025
Exercise(M)
Direct
229.5K shares-
VRNA
Verona Pharma plc
Jun 11, 2025
Sale(S)
Direct
400K shares at avg. $11.40$4.6M
VRNA
Verona Pharma plc
May 29, 2025
Sale(S)
Direct
208.7K shares at avg. $9.33$1.9M
VRNA
Verona Pharma plc
May 28, 2025
Sale(S)
Direct
157.7K shares at avg. $9.30$1.5M
VRNA
Verona Pharma plc
May 27, 2025
Sale(S)
Direct
33.6K shares at avg. $9.53$320K
VRNA
Verona Pharma plc
May 2, 2025
Sale(S)
Direct
400K shares at avg. $9.09$3.6M
VRNA
Verona Pharma plc
May 1, 2025
Sale(S)
Direct
108.3K shares at avg. $8.95$969K
VRNA
Verona Pharma plc
May 1, 2025
Sale(S)
Direct
78.7K shares at avg. $8.95$705K
VRNA
Verona Pharma plc
May 1, 2025
Exercise(M)
Direct
200K shares-
VRNA
Verona Pharma plc
Apr 29, 2025
Sale(S)
Direct
90.4K shares at avg. $8.98$811K
VRNA
Verona Pharma plc
Apr 29, 2025
Exercise(M)
Direct
229.5K shares-
VRNA
Verona Pharma plc
Apr 29, 2025
Award(A)
Restricted Share Units
Direct
675K shares-
VRNA
Verona Pharma plc
Feb 3, 2025
Tax Payment(F)
Direct
166.7K shares at avg. $7.16$1.2M
VRNA
Verona Pharma plc
Feb 1, 2025
Award(A)
Direct
200K shares-

		Type	Shares	Price		Ownership
Jul 7, 2026	VOR Vor Biopharma Inc.	Award(A) Stock Option (Right to Buy)	42,658	-	-	Direct
Jan 5, 2026	SABS SAB Biotherapeutics, Inc.	Award(A) Stock Option (right to buy)	240,000	-	-	Direct
Oct 7, 2025	VRNA Verona Pharma plc	Exercise(M)	3,285,280	-	-	Direct
Oct 7, 2025	VRNA Verona Pharma plc	Award(A) Restricted Share Unit	1,649,952	-	-	Direct
Oct 7, 2025	VRNA Verona Pharma plc	Disposition(D)	3,285,280	-	-	Direct
Oct 7, 2025	VRNA Verona Pharma plc	Disposition(D)	12,176,144	-	-	Direct
Aug 29, 2025	VRNA Verona Pharma plc	Gift(G)	1,200,000	-	-	Direct
Aug 1, 2025	VRNA Verona Pharma plc	Exercise(M)	255,696	-	-	Direct
Aug 1, 2025	VRNA Verona Pharma plc	Sale(S)	208,912	$13.14	$2,745,877	Direct
Jul 8, 2025	VRNA Verona Pharma plc	Tax Payment(F)	90,320	$11.44	$1,033,378	Direct
Jul 7, 2025	VRNA Verona Pharma plc	Award(A) Restricted Share Units	675,048	-	-	Direct
Jul 7, 2025	VRNA Verona Pharma plc	Exercise(M)	229,512	-	-	Direct
Jun 11, 2025	VRNA Verona Pharma plc	Sale(S)	400,000	$11.40	$4,560,520	Direct
May 29, 2025	VRNA Verona Pharma plc	Sale(S)	208,696	$9.33	$1,947,593	Direct
May 28, 2025	VRNA Verona Pharma plc	Sale(S)	157,704	$9.30	$1,466,805	Direct
May 27, 2025	VRNA Verona Pharma plc	Sale(S)	33,600	$9.53	$320,181	Direct
May 2, 2025	VRNA Verona Pharma plc	Sale(S)	400,000	$9.09	$3,637,520	Direct
May 1, 2025	VRNA Verona Pharma plc	Sale(S)	108,272	$8.95	$969,056	Direct
May 1, 2025	VRNA Verona Pharma plc	Sale(S)	78,736	$8.95	$704,703	Direct
May 1, 2025	VRNA Verona Pharma plc	Exercise(M)	200,000	-	-	Direct
Apr 29, 2025	VRNA Verona Pharma plc	Sale(S)	90,360	$8.98	$811,433	Direct
Apr 29, 2025	VRNA Verona Pharma plc	Exercise(M)	229,512	-	-	Direct
Apr 29, 2025	VRNA Verona Pharma plc	Award(A) Restricted Share Units	675,000	-	-	Direct
Feb 3, 2025	VRNA Verona Pharma plc	Tax Payment(F)	166,728	$7.16	$1,194,189	Direct
Feb 1, 2025	VRNA Verona Pharma plc	Award(A)	200,000	-	-	Direct

1-25 of 46 transactions

About ZACCARDELLI DAVID

ZACCARDELLI DAVID (SEC CIK 0001627642) files insider reports with the SEC as Director of Vor Biopharma Inc. (VOR), Director of SAB Biotherapeutics, Inc. (SABS) and President and CEO of Verona Pharma plc (VRNA).

Signal8 holds 22 ownership filings by ZACCARDELLI DAVID (2 Form 3, 20 Form 4), filed between Sep 13, 2024 and Jul 9, 2026. Those filings report 46 transactions, from Aug 7, 2024 to Jul 7, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on ZACCARDELLI DAVID's filings is in BOSTON, MA.

Recent filings by ZACCARDELLI DAVID

Jul 7, 2026: Grant or award of VOR derivative securities (Form 4, code A).
Jan 5, 2026: Grant or award of SABS derivative securities (Form 4, code A).
Oct 7, 2025: Option exercise of VRNA shares (Form 4, code M).
Oct 7, 2025: Grant or award of VRNA derivative securities (Form 4, code A).
Oct 7, 2025: Disposition to issuer transactions of VRNA shares (2 lines, Form 4, code D).

Other insiders filing for Vor Biopharma Inc. (VOR)

RA CAPITAL MANAGEMENT, L.P., 10% Owner
Detheux Michel, Director
Namouni Fouad, Director
Joustra Wouter, Director
Kalir Erez, Director
Cumbo Alexander, Director

How to read Form 4 transaction codes